Stage 2 Stocks in Diagnostics & Research
31 US stocks in Diagnostics & Research are in Stage 2, the advancing phase of Weinstein's stage analysis. Listed below: those priced at $5 or more and trading at least $1 million a day on average, ranked by setup score and updated after every close (last close Oct 23, 2026).
| Stock | Close | 1D | Setup | Weeks in stage |
|---|---|---|---|---|
| CDNA CareDx, Inc. | $69.21 | +0.07% | 8.2 | 24 |
| MTD Mettler-Toledo International, Inc. | $1,670.29 | -0.85% | 7.9 | 9 |
| A Agilent Technologies, Inc. | $173.07 | -0.47% | 7.8 | 13 |
| RVTY Revvity, Inc. | $158.77 | +0.90% | 7.8 | 18 |
| CRL Charles River Laboratories International, Inc. | $345.37 | +1.68% | 7.8 | 16 |
| NTRA Natera, Inc. | $403.95 | +0.64% | 7.6 | 20 |
| ILMN Illumina, Inc. | $269.42 | +0.01% | 7.4 | 24 |
| QGEN Qiagen N.V. | $50.39 | +0.34% | 7.0 | 6 |
| LH Labcorp Holdings Inc. | $328.95 | -0.30% | 7.0 | 14 |
| GRAL GRAIL, Inc. | $132.55 | +4.32% | 6.7 | 7 |
| WAT Waters Corporation | $453.67 | -0.42% | 6.5 | 17 |
| ICLR ICON plc | $185.27 | -0.09% | 6.1 | 13 |
| TMO Thermo Fisher Scientific Inc | $673.82 | -0.40% | 5.7 | 10 |
| DHR Danaher Corporation | $230.50 | +0.33% | 5.7 | 7 |
| MEDP Medpace Holdings, Inc. | $669.20 | +2.33% | 5.6 | 11 |
| IQV IQVIA Holdings, Inc. | $279.36 | +0.37% | 5.3 | 12 |
| PSNL Personalis, Inc. | $15.85 | +0.19% | 4.9 | 17 |
| ADPT Adaptive Biotechnologies Corporation | $25.51 | +4.51% | 4.9 | 17 |
| NEO NeoGenomics, Inc. | $16.59 | +1.22% | 4.9 | 16 |
| GH Guardant Health, Inc. | $169.08 | +3.77% | 4.8 | 22 |
| DGX Quest Diagnostics Incorporated | $241.89 | -0.57% | 4.7 | 17 |
| FRNM Freenome, Inc. | $12.77 | -2.52% | 4.4 | 8 |
| BDSX Biodesix, Inc. | $21.18 | -11.53% | 4.3 | 18 |
| SHC Sotera Health Company | $18.10 | -0.17% | 4.3 | 14 |
| XGN Exagen Inc. | $7.27 | -2.81% | 4.2 | 10 |
| RDNT RadNet, Inc. | $70.34 | +0.11% | 4.0 | 9 |
| CSTL Castle Biosciences, Inc. | $33.08 | -0.33% | 3.9 | 6 |
| FLGT Fulgent Genetics, Inc. | $20.10 | +0.55% | 3.2 | 4 |
| WGS GeneDx Holdings Corp. Class A | $56.15 | -16.37% | 2.3 | 4 |
Diagnostics & Research: quick answers
Which stocks in Diagnostics & Research are in an uptrend?
As of Oct 23, 2026, 31 US stocks in Diagnostics & Research are in Stage 2, the uptrend phase. The largest by market value are Thermo Fisher Scientific, Danaher, Natera, Agilent Technologies and IQVIA Holdings.
How many stocks in Diagnostics & Research are in Stage 2?
31 of the 44 stocks we track in Diagnostics & Research (70.5%) are in Stage 2. 3 are basing in Stage 1, 5 are topping in Stage 3 and 5 are in a Stage 4 downtrend. That share is unchanged over the last 20 sessions.
Which stocks in Diagnostics & Research entered Stage 2 recently?
2 stocks entered Stage 2 in the last four weeks: Fulgent Genetics (week 4) and GeneDx Holdings (week 4).
Daily screens
Every one recalculated after the close, with the exact criteria published on the page.
Stage 2 in other sectors & industries
US stocks in a confirmed uptrend (Stage 2, Weinstein’s advancing phase), grouped by sector and industry and ranked by setup score.